Rationing

Why this matters in health economics

No health system, however rich, can fund every intervention that might help every person who could benefit. Need is effectively unbounded — it expands with ageing populations, new technologies, and rising expectations — while budgets, staff, beds, and clinician-hours are finite. Rationing is the name economists give to the allocation of a scarce resource among competing claims, and in health it is not an aberration to be engineered away but a permanent condition to be managed well.

The stakes are unusually high because the currency is not money but health, and sometimes life. A decision to fund an expensive new cancer drug is, whether or not anyone says so, a decision not to fund something else — more district nurses, a mental-health service, a maternity refurbishment. That displaced benefit is invisible: it has no name, no patient advocacy group, and no headline. The discipline of rationing is largely the discipline of making that invisible loss visible and weighing it honestly.

Rationing is also where economics meets legitimacy. When a public payer says no to a named patient, it is spending not only money but public trust. Get the process wrong — opaque, inconsistent, capturable by the loudest voice — and even correct decisions lose their authority. This chapter is about the mechanisms societies use to say no, and how to say it in a way that a reasonable person, even one who loses, can accept as fair.

Core concepts

Scarcity makes rationing unavoidable. Because resources are finite and wants are not, some claims must go unmet. Rationing is simply the mechanism — market price, queue, rule, or lottery — that decides which. The economist's contribution is to insist that the loss be counted, not wished away, and that the mechanism be chosen deliberately rather than inherited by accident.

Opportunity cost is the true measure of what rationing costs. At the system level, the cost of funding an intervention is not its price tag but the health that would have been produced by the next-best use of the same money. When a fixed budget funds a high-cost, low-value service, the loss falls on unidentified patients elsewhere in the system whose care is displaced. This system-level opportunity cost is the moral and analytical heart of priority-setting; the evaluation methods that estimate it — quality-adjusted life years, incremental cost-effectiveness ratios, and thresholds — belong to Chapter 2.1 — Economic Evaluation, which this chapter draws on rather than repeats.

Explicit and implicit rationing differ in who decides and who can see. Explicit rationing sets out rules and criteria in the open: a published benefits package, a technology-appraisal decision, an eligibility threshold. Implicit rationing hides the choice inside clinical discretion, waiting times, and administrative friction — no one announces that a treatment is unavailable; it is simply never quite offered, or offered too late. Explicit rationing is accountable but politically costly, because the losers are visible and can protest. Implicit rationing is politically comfortable but arbitrary, inconsistent, and prone to inequity. The Oregon Health Plan of the early 1990s is the canonical attempt at fully explicit rationing: the US state ranked hundreds of condition–treatment pairs by priority and drew a funding line, exposing both the appeal and the political difficulty of putting the list in the open.

Rationing mechanisms vary by system type. Care can be rationed by waiting list (delay allocates non-urgent care, common in tax-funded systems such as the United Kingdom's National Health Service), by cost-sharing (co-payments and deductibles that ration by price, common in social- and private-insurance systems), by defined benefit packages (an explicit list of what is covered), by health technology assessment (HTA) that gates new technologies on value, and by clinical prioritization (triage by need or expected benefit). Most systems use several at once. How a system finances care shapes which mechanisms it reaches for (see Chapter 3.1 — Health Systems).

Procedural fairness can substitute for consensus on outcomes. People disagree deeply about what a fair allocation looks like, and no formula resolves those disagreements. The philosopher Norman Daniels and psychiatrist James Sabin argued that legitimacy therefore rests on how decisions are made — a framework they called "accountability for reasonableness". It sets four conditions: publicity (decisions and their rationales are public), relevance (rationales rest on reasons fair-minded people accept as relevant), revisability (there is a mechanism to appeal and revise), and enforcement (the first three are regulated). This is procedural justice applied to the clinic and the treasury.

Disinvestment is rationing's neglected other half. Priority-setting is usually framed as choosing what to add, but a fixed budget means adding one thing requires releasing resources from another. Disinvestment is the deliberate withdrawal or reduction of interventions that deliver little or no value for their cost, freeing that money for higher-value uses. It is politically harder than investment — taking something away creates identifiable losers — but a system that only ever adds will price itself out of its own priorities. Tools such as programme budgeting and marginal analysis exist to make disinvestment systematic rather than a series of crises.

Distributive justice sets the terms rationing must satisfy. How society ought to share out a scarce good — equally, by need, by capacity to benefit, or to favour the worst-off — is a question of distributive justice that economics informs but cannot settle. Rationing rules encode a distributive theory whether or not they admit it. The formal equity concepts and their measurement belong to Chapter 3.4 — Equity; here the point is that every priority-setting rule takes a position on fairness and should be able to defend it.

Best practices

1. Accept that you are already rationing, and make it deliberate. The first discipline is honesty: a queue, a restrictive formulary, and an exhausted budget are all rationing, whether or not anyone uses the word. Denial forces rationing underground, where it becomes implicit, inconsistent, and unaccountable. Naming it lets you choose the mechanism on purpose and defend it in public.

2. Prefer explicit rationing where the decision can bear public scrutiny. Explicit rules — published criteria, benefit packages, appraisal decisions — are consistent, auditable, and correctable in a way that clinician-by-clinician discretion is not. The cost is political exposure: visible losers protest, and leaders must hold the line. Reserve implicit mechanisms for the genuinely individual clinical judgements that no rule can anticipate, not as a hiding place for choices you would rather not own.

3. Build the process on accountability for reasonableness. Publish decisions and the reasons behind them; ensure those reasons are ones fair-minded people accept as relevant; provide a genuine route to appeal and revise; and regulate the whole to keep it honest. When people cannot agree on the right answer, a process they recognize as fair is what confers legitimacy. This is the most portable single lesson in the priority-setting literature and applies in tax-funded, insurance-based, and low-income systems alike.

4. Make the opportunity cost visible in every funding decision. For every proposed yes, ask what is displaced and who bears the loss. A decision memo that lists only the benefits of the new intervention is hiding half the analysis; require the counterfactual — the health foregone elsewhere — to appear alongside it. This reframes rationing from "denying a patient" to "choosing between patients", which is what it actually is.

5. Pair every investment decision with a disinvestment mechanism. In a fixed budget, saying yes without saying a corresponding no simply defers the reckoning. Maintain a standing process to identify low-value care — interventions with weak evidence, better substitutes, or poor cost-effectiveness — and to release its resources. Programme budgeting and marginal analysis, "do-not-do" lists, and value-based reviews turn disinvestment from an annual crisis into routine housekeeping.

6. Manage waiting as a rationing tool, not merely a queue to be shortened. Where care is rationed by delay, the design of the queue is a policy choice with equity consequences. Prioritize by clinical need and expected benefit rather than first-come-first-served, publish waiting-time data, and watch for the ways queues quietly disadvantage the less assertive and less informed. Simply pouring money into shorter waits, without a rule for who waits, can worsen fairness even as averages improve.

7. Separate the value judgement from the technical estimate, and be explicit about both. Analysts can estimate costs, benefits, and cost-effectiveness; they cannot decide how much weight to give the severity of a condition, the age of a patient, or the rarity of a disease. Keep the technical appraisal (Chapter 2.1 — Economic Evaluation) distinct from the social value judgements applied on top of it, and state the latter openly so they can be debated rather than smuggled in.

8. Design against the rule of rescue and identifiable-victim bias. Systems reliably overspend on visible, named individuals in immediate peril and underspend on the larger, statistical, invisible population who lose out. A good process anticipates this pull and holds the line for the unidentified patients displaced by a high-profile funding decision. Naming the trade-off in the room — "this money is the district's diabetes service" — is a practical counterweight.

9. Set decision rules in advance, not in the heat of a case. Agreeing criteria before a contested individual case arrives protects both the decision and the decision-maker from being captured by advocacy, media pressure, or the loudest voice. Rules made under pressure for one patient become precedents that distort the next hundred. Publish the criteria, apply them consistently, and route exceptions through the same transparent appeal process.

10. Involve the public in the rules, not just the outcomes. Citizens and patients can meaningfully shape the principles of rationing — what counts as need, how to weigh severity, whether to favour the worst-off — even when they cannot be in the room for each decision. Deliberative methods (citizens' juries, structured consultation) build both better rules and durable legitimacy. Involvement is not a substitute for deciding; it is what makes the eventual no easier to accept.

11. Audit for consistency and drift. A rationing framework degrades quietly: exceptions accumulate, thresholds erode, and similar cases start getting different answers across regions or clinicians. Periodically review decisions for consistency, look for unwarranted geographic variation (the "postcode lottery" pattern), and feed the findings back into the rules. Legitimacy depends on like cases being treated alike.

12. Protect the process from short-term political rescue. The most common way a good rationing system fails is a special fund or ministerial override created to bypass it for a popular cause — often a specific disease or drug. Such carve-outs feel compassionate and are corrosive: they reward advocacy over evidence and quietly transfer resources from the unheard to the heard. Guard the integrity of the process even when doing so is unpopular.

Questions to discuss with your team

1. Where in our system are we rationing implicitly, and would we defend those choices if they were made explicit? Every organization rations somewhere — in waiting lists, restrictive criteria applied inconsistently, referral thresholds that vary by clinician, or services that are technically available but practically hard to reach. The honest exercise is to surface these hidden choices and ask whether each would survive being written down and published. Some will be reasonable clinical judgements that resist codification; others will be arbitrary or inequitable patterns that persist only because no one has to own them. An honest answer distinguishes the two, names who currently loses under the implicit arrangement, and decides which choices should be made explicit even at the cost of political exposure. The goal is not to eliminate discretion but to stop using it as camouflage.

2. What is our mechanism for saying no, and does it meet the test of accountability for reasonableness? It is easy to have a process for approving new spending and no equivalent process for refusing or withdrawing it. Ask whether your refusals are published with their reasons, whether those reasons are ones a reasonable objector would accept as relevant, whether there is a real route to appeal, and who guards the whole. A useful stress test is a recent contested decision: could you show a losing patient the rationale, the criteria, and the appeal path, and expect them to concede it was fair even while disagreeing? An honest answer admits where the process is currently ad hoc, capturable, or invisible, and commits to closing those gaps before the next high-profile case arrives rather than during it.

3. When we fund something new, what are we willing to stop doing, and who decides? A fixed budget makes every yes a no somewhere, but most organizations plan investment far more carefully than disinvestment. Ask whether your investment cases are required to name what they displace, whether you maintain a live list of low-value care that could be reduced, and whether anyone owns disinvestment as a standing responsibility rather than an emergency. The tension is real: disinvestment creates identifiable losers — a service, a team, a patient group — while the beneficiaries of the freed resources are diffuse and unnamed. An honest answer resists the temptation to fund the new thing on hope of future savings, and instead pairs each material investment with a concrete, owned decision about what gives way.

4. When we ration by waiting, who is actually waiting, and did we design that on purpose? A queue is a rationing mechanism, but it is often the one no one admits to designing — care is allocated by delay, and delay lands unevenly. Ask whether your waiting lists are ordered by clinical need and expected benefit or simply by arrival order, whether you publish waiting-time data, and whether you know how waits differ by deprivation, language, health literacy, or distance from the service. The uncomfortable finding is usually that the queue quietly favours the assertive, the informed, and the well-connected, who escalate, re-refer, and navigate faster than others. Pouring money into shorter average waits can leave that inequity untouched or even widen it, because the same people capture the improvement. An honest answer treats the design of the queue — the prioritization rule, the transparency, the escalation routes — as a deliberate equity choice, not an operational afterthought (see Chapter 3.4 — Equity).

5. How do we hold the line for the patients we cannot see? Systems reliably overspend on the visible, named individual in immediate peril — the rule of rescue at work — and underspend on the larger, statistical population who lose out silently when that money is committed. Ask whether, in your most recent high-profile funding decision, anyone in the room spoke for the unidentified patients whose care was displaced, and whether your process gives them any standing at all. The tension is that the identifiable victim has a name, a face, a family, and often a campaign, while the displaced have none of these — yet they are just as real and usually more numerous. A good process anticipates this pull and builds in a deliberate counterweight: naming the specific service the money would otherwise fund, agreeing criteria before the emotive case arrives, and refusing to let one vivid story rewrite the rules for the next hundred quiet ones. An honest answer admits where compassion for the visible has quietly transferred resources from the unheard, and commits to a discipline that resists it without pretending the human pull away.

6. Have we let the public shape the principles of our rationing, or only informed them of the results? Citizens can meaningfully help decide what counts as need, how much extra weight severity deserves, and whether to favour the worst-off — the value judgements no formula settles — even when they cannot sit in on each individual decision. Ask whether you have ever convened genuine deliberation on the principles, through citizens' juries or structured consultation, or whether your public involvement is confined to explaining decisions after they are made. The distinction matters because involvement in the rules builds durable legitimacy, whereas involvement only in outcomes reads as consultation theatre and erodes trust when a hard no lands. There is a real tension: deliberation is slow, can be captured by organized interests, and does not relieve you of the duty to decide. An honest answer is clear about which parts of rationing are technical (and belong to analysts), which are value judgements (and belong to the public), and whether your current arrangements actually give citizens a hand on the second.

In practice: a health economics example

The fictional middle-income country of Solavia is expanding its national health-insurance scheme towards universal health coverage and must decide which services its benefit package will guarantee. The budget is real and binding: the Ministry of Health has been given a fixed per-capita envelope, and every service added to the package is a service the country commits to funding for its whole insured population. The health minister wants to include a newly licensed but expensive biologic therapy for a chronic autoimmune condition, championed by a well-organized patient association and featured sympathetically in the national press.

Solavia's newly created priority-setting committee runs the request through its process rather than the minister's inbox. The technical team estimates the therapy's cost per quality-adjusted life year using the methods of Chapter 2.1 — Economic Evaluation, and finds it several times higher than the country's provisional cost-effectiveness threshold, which was set with reference to what a unit of the health budget already buys elsewhere. Crucially, the committee insists on stating the opportunity cost in concrete terms: funding the biologic for the eligible population would consume roughly the same resources as extending the scheme's primary-care maternal and child-health services to two under-served rural provinces.

The committee applies accountability for reasonableness deliberately. It publishes the appraisal, the threshold, and the displacement analysis; it holds an open session where the patient association, clinicians, and rural health advocates each make their case; and it records its reasoning. It declines to add the biologic to the guaranteed package at the current price, but does three things that make the no legitimate: it opens a negotiation with the manufacturer for a managed-entry price that would bring the therapy within range, it establishes a transparent individual-appeal route for exceptional clinical cases, and it commits to re-review when new evidence or a lower price arrives.

The committee then closes the loop on disinvestment. Reviewing the existing package, it identifies an older, widely used but poorly evidenced injectable treatment for the same condition and a routine imaging practice with little effect on outcomes, and it phases both down — releasing resources that part-fund the rural primary-care expansion. The decision is unpopular with the patient association and awkward for the minister, but it survives scrutiny in parliament precisely because the process was public, the reasons were relevant, the trade-off was named, and there was a route to revisit it. Solavia has not escaped rationing; it has done it in a way its citizens can recognize as fair.

Four sector lenses

Startup

A digital-health start-up rarely thinks of itself as rationing, yet its pricing, eligibility rules, and feature gating allocate a scarce product among users. If it sells into public payers, it will meet rationing as a gatekeeper: its route to scale runs through benefit packages, formularies, and HTA, so it must build the value evidence that lets a payer say yes without displacing something more valuable. The pragmatic move is to design for the payer's opportunity-cost test from the outset — showing not just that the product works, but that it is a better use of a fixed budget than the alternatives it would displace. Early-stage firms that treat priority-setting as a distant regulatory hurdle rather than a core design constraint tend to build things no rational payer can fund.

Small business

A small but established provider — a GP partnership, a single clinic, a care home, or a niche device supplier — rations every day within a fixed contract or a capped budget, but with settled routines rather than a start-up's improvisation. Its allocation choices are concrete and local: which patients get the scarce appointment slots, how a limited drugs or equipment budget is spent, whom the waiting list serves first. Because the same clinicians and managers make these calls repeatedly, the risk is not chaos but quiet, unexamined convention — informal rules that have never been written down, tested for consistency, or checked for who they disadvantage. The practical move is to make the standing rule explicit and defensible: a published prioritization criterion for appointments, a transparent basis for the referral threshold, and a note of the reasons when an exception is made. Unlike a large enterprise it has no committee or analytics team, so legitimacy comes from plain, consistent practice its patients can understand and its staff can apply the same way each time.

Enterprise

A large hospital group, integrated provider, or insurer rations continuously through capacity decisions, network design, prior authorization, and formulary management. At this scale the risk is that rationing is real but diffuse — dispersed across thousands of local operational choices with no coherent, defensible framework and no consistency across sites. The enterprise task is to make the implicit explicit: standard prioritization criteria, transparent waiting-list management, a disciplined disinvestment programme, and audit for the geographic variation that erodes fairness and invites regulatory attention. Where an insurer uses cost-sharing to ration by price, it must watch for the equity damage co-payments do to lower-income members, since price-rationing falls hardest on those least able to pay (see Chapter 3.4 — Equity).

Government

A ministry or national payer rations for a whole population under intense political and public scrutiny, and here procedural fairness is not a nicety but the source of authority to act. Government owns the hard architecture — the benefit package, the HTA body, the threshold, the appeals mechanism — and must protect it from the special funds and ministerial overrides that undo it one popular cause at a time. Its comparative advantage is legitimacy through process: the ability to convene public deliberation, publish reasons, and hold consistent rules across the system. Government also carries the disinvestment burden that no one else will, because only it can withdraw funding at scale and answer for it in public.

Common failure modes

• Denying that rationing happens. Insisting "we don't ration" pushes allocation into queues and discretion, where it becomes arbitrary and hidden. Fix: name the rationing you already do and choose the mechanism deliberately.

• Implicit rationing by default. Leaving allocation to unmonitored clinical discretion and administrative friction produces inconsistency and the "postcode lottery". Fix: make defensible decisions explicit, publish criteria, and audit for variation.

• Counting only the benefits of a yes. Approving new spending without stating what it displaces hides the opportunity cost and the patients who bear it. Fix: require a displacement analysis in every material funding decision.

• Investment without disinvestment. Adding services on the promise of future savings, while never withdrawing low-value care, quietly bankrupts the priorities you claim to hold. Fix: pair investment with an owned, concrete disinvestment.

• Capture by the rule of rescue. Overspending on the visible, identifiable patient in peril while the larger statistical population loses out unseen. Fix: name the displaced, unidentified patients in the room and set rules before the case arrives.

• Special funds and overrides. Creating carve-outs for popular diseases or drugs rewards advocacy over evidence and drains resources from the unheard. Fix: route all claims through one transparent process and defend its integrity.

• Process theatre. Publishing a framework while real decisions are made informally elsewhere destroys trust faster than having no framework at all. Fix: ensure the published process is the actual one, with genuine appeal and revision.

Maturity model

Checklist

• We have named where in our system care is rationed, and by which mechanism.
• Major allocation decisions are made explicitly, with published criteria.
• Our process meets accountability for reasonableness: public reasons, relevant rationales, an appeal route, and enforcement.
• Every material funding decision states its opportunity cost and who bears the displaced loss.
• Each investment is paired with a concrete, owned disinvestment.
• Waiting lists are prioritized by need and benefit, published, and checked for equity effects.
• Technical estimates are kept separate from, and stated alongside, the social value judgements applied to them.
• Decision criteria are agreed before contested individual cases arise.
• The public has shaped the principles of rationing, not only received its outcomes.
• We audit decisions for consistency and geographic variation, and feed findings back into the rules.
• The process is protected from special funds and ad hoc overrides.

Key sources

• Daniels, N. & Sabin, J. — Setting Limits Fairly: Can We Learn to Share Medical Resources? — the foundational statement of accountability for reasonableness.
• Coulter, A. & Ham, C. (eds.) — The Global Challenge of Health Care Rationing — comparative survey of priority-setting across systems.
• Ubel, P. — Pricing Life: Why It's Time for Health Care Rationing — on the psychology and ethics of saying no.
• Ham, C. — "Health care rationing" — BMJ (1995) — concise framing of explicit vs implicit rationing.
• Oregon Health Plan — the canonical explicit-rationing experiment in benefit-package prioritisation.
• NICE methods guidance — England's National Institute for Health and Care Excellence — a standing exemplar of explicit, appealable HTA-based priority-setting (https://www.nice.org.uk/process/pmg36).
• World Health Organization — health financing and universal health coverage benefit-package publications — guidance for priority-setting worldwide, including low- and middle-income settings.

References

1. Rationing — Wikipedia — https://en.wikipedia.org/wiki/Rationing
2. Health care rationing — Wikipedia — https://en.wikipedia.org/wiki/Health_care_rationing
3. Scarcity — Wikipedia — https://en.wikipedia.org/wiki/Scarcity
4. Opportunity cost — Wikipedia — https://en.wikipedia.org/wiki/Opportunity_cost
5. Waiting list — Wikipedia — https://en.wikipedia.org/wiki/Waiting_list
6. Cost sharing — Wikipedia — https://en.wikipedia.org/wiki/Cost_sharing
7. Health technology assessment — Wikipedia — https://en.wikipedia.org/wiki/Health_technology_assessment
8. Oregon Health Plan — Wikipedia — https://en.wikipedia.org/wiki/Oregon_Health_Plan
9. Procedural justice — Wikipedia — https://en.wikipedia.org/wiki/Procedural_justice
10. Norman Daniels — Wikipedia — https://en.wikipedia.org/wiki/Norman_Daniels
11. Distributive justice — Wikipedia — https://en.wikipedia.org/wiki/Distributive_justice
12. Programme budgeting — Wikipedia — https://en.wikipedia.org/wiki/Programme_budgeting
13. Rule of Rescue — Wikipedia — https://en.wikipedia.org/wiki/Rule_of_Rescue
14. Daniels, N. & Sabin, J. — Setting Limits Fairly: Can We Learn to Share Medical Resources? — Oxford University Press.
15. Coulter, A. & Ham, C. (eds.) — The Global Challenge of Health Care Rationing — Open University Press.
16. NICE health technology evaluations: the manual (PMG36) — National Institute for Health and Care Excellence — https://www.nice.org.uk/process/pmg36
17. Health economics: a guide for public health teams — GOV.UK — https://www.gov.uk/guidance/health-economics-a-guide-for-public-health-teams